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Abstract
Background: Telomerase, which is active early in development and later in stem and germline cells, is also active in the
majority of human cancers. One of the known functions of telomerase is to extend the ends of linear chromosomes,
countering their gradual shortening at each cell division due to the end replication problem and postreplication processing.
Telomerase concentration levels vary between different cell types as well as between different tumors. In addition variable
telomerase concentrations will exist in different cells in the same tumor when telomerase inhibitors are used, because of
limitations of drug delivery in tissue. Telomerase extends short telomeres more frequently than long telomeres and the
relation between the extension frequency and the telomere length is nonlinear.
Methodolgy/Principal Findings: Here, the biological data of the nonlinear telomerase-telomere dynamics is incorporated in
a mathematical theory to relate the proliferative potential of a cell to the telomerase concentration in that cell. The main
result of the paper is that the proliferative capacity of a cell grows exponentially with the telomerase concentration.
Conclusions/Significance: The theory presented here suggests that long term telomerase inhibition in every cancer
progenitor or cancer stem cell is needed for successful telomere targeted cancer treatment. This theory also can be used to
plan and asses the results of clinical trials targeting telomerase.
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Introduction
Telomeres protect the ends of linear chromosomes from being
recognized by the DNA repair system as double strand breaks inneed
of repair[1,2,3]. In the absence of a lengthening mechanism, during
DNA replication telomeres lose nucleotides partly due to the inability
of DNA polymerase to replicate their ends[4,5] and partly due to
post-replication processing needed to create a single strand
overhang[6], which is part of the telomere protective structure
known as shelterin[7]. In the absence of a telomere extension
mechanism, a dividing cell will acquire a short telomere incapable of
maintaining the shelterin integrity. This may trigger a p53 dependent
checkpoint response leading to cell cycle arrest[8,9,10,11]. Cells,
however, have developed a mechanism for countering this gradual
loss of telomeric DNA. In some organisms telomere recombination
has emerged as a telomere maintenance mechanism[12], while in
others, including humans, telomere length homeostasis is accom-
plished by telomerase, a ribonucleoprotein complex that provides
RNA template sequence for telomeric DNA extension[2,13]. Normal
human somatic cells have telomerase levels below the level required
for telomere maintenance and their telomeres shorten with each cell
division[14]. There is substantial evidence that short telomeres limit
cell’s ability to proliferate and that gradual telomere shortening in
normal somatic cells leads to their finite proliferative capacity[8,15].
Cancer cells on the other hand acquire infinite or very large
proliferative potential (PP) (the potential number of cell divisions a cell
can undergo before entering senescence) by reactivating a program
for telomere homeostasis[16]. Telomerase is also detectible in stem
cells[17], and these cells have large, but limited proliferative capacity.
In most tumours, cancer cells re-express telomerase. In some cancers,
there is no detectible telomerase and these cancer cells use an
alternative lengthening of telomeres (ALT), mechanism for telomere
maintenance. ALT is believed to be recombination based
[18,19,20,21] and is characterized by long and heterogeneous
telomeres ranging from 2 kb to 50 kb[22], extra-chromosomal
telomere repeats[23], and ALT associated promyelocytic leukimia
(PML) nuclear bodies that contain PML protein, TRF1, TRF2,
replication factor A, Rad51, and Rad52[24]. There are also cancer
cells that use neither telomerase, nor have the characteristic
signatures of ALT and in these instances it is not clear how telomeres
are replenished. There is some evidence that both telomerase and
ALT might be active in different cells of the sametumor[25]. Because
telomerase [6] is expressed in most human cancers, it is an attractive
therapeutic target[26,27,28,29]. Telomerase inhibition does not
typically reactivate the ALT mechanism, although in one instance
an ALT phenotype emerged after telomerase suppression[11]. In
addition suppressing simultaneously mTerc and Wrn in mouse cells
leads to increased telomere-telomere recombination rates and an
activation of ALT[30]. Telomerase re-activation seems to inhibit the
recombination based maintenance mechanism in human cells[31].
At each cell division telomere length regulation consists of basal
telomere loss and telomerase facilitated telomere gain. In short this
can be expressed as
change of telomere length ðÞ
~{ basal loss ðÞ z telomere gain ðÞ   extension probability ðÞ :
The extension probability in Saccharomyces cerevisiae[32,33,34],
human cancer cells, and in telomerase positive, normal human
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the extension probability or the extension frequency is a sigmoid
type of curve and was well fitted by a logistic regression. In wild
type cells with sufficient telomerase expression for maintaining
telomere homeostasis, telomeres are maintained at an equilibrium
length. In S. cerevisiae this equilibrium length is approximately 300
base pairs (bp)[33], while in immortalized human cells it is
between 5000 and 15000 bp[14]. The basal telomere loss in S.
cerevisiae is 3 nucleotides (nt) per generation[35] and while in
human cells it is between 50 and 200 bp[14]. Larger telomere
rapid deletions (T-RD) may occur as well, due to DNA double
strand breaks or errors during DNA replication[36]. The number
of telomere repeats added by telomerase in a single cell cycle in vivo
varies from few to more than a hundred nucleotides in S.
cerevisiae[33] and up to 800 in human super-telomerase cells[37].
Telomerase adds nucleotides to S. cerevisiae telomeres in late S
phase, but does not replenish all telomeres at each cell replication
either because it might not be available at all telomeres during that
time or because when available at a telomere it may not be able to
extend the telomere. Recent data suggests that in budding
yeast[33] telomeres switch back and forth between two states:
extendible or open state, which allows telomerase to associate with
the telomere and a nonextendible or closed state, which prevents
telomerase from associating with the telomere. This binary
response suggested in this study is consistent with the sigmoid
function used to fit the data. The oscillation frequency between
these two states is higher for shorter telomeres and this leads to a
higher probability for a telomerase complex to associate with these
telomeres. Even when telomerase associates with a telomere it
might not extend that telomere. Whether or not a telomerase
associated with a telomere processes it or not depends on its
length[32,33,37] and perhaps on the state of the shelterin
complex. In S. cerevisiae the repeat addition processivity (the
number of telomere repeats added per round of DNA replication)
is higher at shorter telomeres[32], but is lower than in human cells.
In human cells telomerase concentrations correlate with increased
repeat addition processivity[38]. In cells in which telomerase is
partly inhibited a new equilibrium length is established by a
feedback control mechanism as shown in S. cerevisiae [33]. Recently
telomerase in human cells was expressed beyond the physiological
limit [37] and in these super-telomerase cells the telomere
extension dynamics did not seem to slow down, continuing with
the same average rate for more than 60 population doublings [37].
This constant rate of elongation suggests that in these cells the
combined probability for a telomere to be in an open state times
the number of base pairs added to the telomere during an
elongation event is a constant that is larger than the basal telomere
loss. In the HEK-293 human cancer cell line the number of
telomerase complexes, 50[39], is approximately few times smaller
than the number of telomeres, suggesting that the telomerase
concentrations are limiting[40,41].
Results
In Fig. 1 the probabilistic and deterministic length control
dynamics is shown for two telomeres with different initial lengths:
one shorter and one longer than the steady state length. The
feedback control steadily increases the length of the shorter and
decreases the length of the longer telomere. The speed of telomere
elongation or depletion is larger the farther a telomere is from the
steady state and becomes zero for telomeres with the steady state
length. For fixed steady state length this speed is controlled by the
parameter T in Eqn.(4). The speed at which the telomeres
approach the steady length depends on the parameters T and m in
the logistic response (Fig. 2). For small T, e.g.=1, m=6001 and
the speed approaches the maximum speed determined by the
basal loss (100 bp/cell divison this model). This is because the
logistic function is zero (one) for longer (shorter) than the steady
length telomeres most of the time. Therefore the curves in Fig. 1,
represent the slowest telomere length dynamics. The choice of
parameters in the logistic probability function is consistent with
current data for S. cerevisiae[33], but for human the telomere length
is not known.
Lowering the telomerase concentration leads to faster decrease
in telomere length (the fastest decrease is set by the basal loss rate).
The first telomere reaching a critical length is expected to trigger a
p53-dependent checkpoint cellular response. In human cells this
critical length is 2000–4000 bp. However, in most cancers the p53
pathway is inactivated and the telomeres continue to decrease in
length until the crisis point is reached. At the crisis point the short
telomeres are only few hundred base pairs in length[42] and
therefore telomerase inhibition is more effective in cancers with an
intact p53 response. In Fig. 3, the telomere erosion is shown for
telomeres with initial length of 6000 bp, corresponding to cells
with different degree of telomerase suppression. In this figure it is
assumed that when the telomerase-telomere fraction is 50/92 the
telomeres are maintained at their steady state length of 6000 bp.
The critical telomerase concentration below which telomeres
reach zero length is 73.6% of 50/92. The time that it takes to
reach crisis (0 in this figure) and thus the PP decreases with
decreasing telomerase concentration. The relation between the
Figure 1. In this figure the time dependence (in cell divisions)
of the average telomere length e is shown. Because the initial
length of the two representative telomeres shown in the figure is
longer (shorter) than the homeostatic length the telomeres gradually
approach the homeostatic length. Adaptive control at the telomere
guarantees that short telomeres are extended and long telomeres are
shortened to the average homeostatic length. The initial telomere
length, the average steady state telomere length and the square root of
t h ev a r i a n c ea r es h o w nf o rt w ot e l o m e r e si nt h ep r e s e n c eo f
telomerase. While at the steady state, the square root of the variance
is small compared to the average telomere length. As the telomere
shortens below 1000 bp these two quantities will become comparable
and large fluctuations may produce a sub-critically short telomere and
trigger p53 independent checkpoint response. The continuous model is
shown with continuous lines.
doi:10.1371/journal.pone.0004622.g001
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Here the normalized telomerase concentration p is relative to the
telomerase-telomere fraction p0=50/92 at which the PP is
infinite, i.e. p=(50/92)p. The dependence of the PP is well
approximated by an exponential in this parameter range:
V~V0zV1ep=p0, with V0=52, V1=8, and p0=0.17. For
p.0.736, the PP of a cell is infinite, i.e. the telomeres are
maintained at a nonzero length.
Telomere elongation by telomerase or for that matter by any
other telomere maintenance mechanism must be such that no
critical or subcritical telomeres occur during this process. This
means that the number of base pairs added per elongation event
minus the telomeric basal loss must be small compared to the
telomere size. On the other hand if this number is too small, the
recovery of a short telomere to the steady state length would be too
slow and a few recombination events may bring the length of a
telomere below the critical length triggering a checkpoint
response. If, however, this number is too large, the frequency at
which the extending state occurs needs to be low. Again, these
large fluctuations may lead a short telomere to the critical length,
because of the high probability that a telomere may not be
extended during several consecutive cell divisions. The parameters
that govern the telomere length homeostasis, the basal loss, the
telomerase concentration, the number of nucleotides added by
telomerase, the equilibrium telomere size, and the probability for
an extendable state have been selected in a range that guarantees
robust telomere maintenance dynamics despite the naturally
occurring noise fluctuations and this may be the clue to why
telomerase levels are tightly regulated.
In the HEK-293 human cancer cell line, 50 telomerase
complexes are present[39] and the availability of telomerase at a
particular telomere depends on whether or not other telomeres are
being extended. The physical mechanism by which telomerase is
being directed preferentially to short telomeres is not clear, but
some details are emerging[43]. In S. cerevisiae, because of the short
Figure 3. In the presence of telomerase inhibitor, telomerase is
incapable of preventing the appearance of a critically short
telomere. The attrition of telomeres at different telomerase inhibition
level is shown for several telomeres with the same initial length. The
time to the crisis point for each cell determines the proliferative
potential of that cell.
doi:10.1371/journal.pone.0004622.g003
Figure 4. The average proliferative potential or the number of
cell divisions before crisis of a population of cells is shown as a
function of the degree of telomerase inhibition p. The parameter
p describes the availability of telomerase and varies between 0 (no
telomerase is available) and 1 (all telomerase is available). The
proliferative potential is averaged over 1000 cells for each inhibition
level and the functional dependence is well approximated by an
exponential function in the interval p=0.0 to p=0.6: V=V0+V1exp(p/p0)
(V0=52, V1=8, and p0=0.17, R=0.99816).
doi:10.1371/journal.pone.0004622.g004
Figure 2. The feedback control function, maintaining the
telomere length, is shown. On this figure the dependence of the
probability (or the frequency), p, for occurrence of the open state on
the telomere length e (in base pairs) is shown. The parameter m in this
function is the telomere length at which the probability for the
extending state is K. The parameter T=1000 determines the slope of
the sigmoid. The choice of T is close to the maximum possible value for
telomere homeostasis at telomere length of 6000 bp (see the text for
an explanation).
doi:10.1371/journal.pone.0004622.g002
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counting mechanism based on the number of nucleotides or of
the number of telomere bound proteins seems to exist. In human
cells telomerase maintains the telomeres at several thousand bp
and the counting mechanism, if it exists, remains unknown. One
possibility is that the shorter the telomere the earlier it becomes
available for elongation in S phase[44] and telomerase binds to it.
The telomerase will bind in a successive order from short to long
telomeres. This may explain why short telomeres are elongated
first and why telomerase is maintained at lower numbers than the
number of chromosome ends. However, the time of telomere
replication is not correlated with their length[45] and a simple
relation between replication time and telomere extendibility is not
likely to exist.
In S. cerevisiae, the nonlinear adaptive control that telomeres
perform through a feedback loop on their extension rate is
performed by the frequency at which an extendible state occurs in
other organisms the mechanism is currently unknown. Because, the
steady state telomere length in human cells is much longer than in S.
cerevesiae the length controlin this case might be accomplished by the
adaptive extension length of the added telomere repeats by
telomerase and not by the frequency of occurrence of the extendible
state. This, alternative mechanism is also captured by the model
introduced here, because D
.
1ze e{m ðÞ =T
  
in Eqn. (4) can be
interpreted as the length of the added telomere repeats by the
telomerase complex. This means that the model is more general
than the specific mechanism of telomere length homeostasis. This
paper is concerned with the dynamics of telomere attrition caused
by telomerase depletion. In this case the speed at which telomerase
replenishes a telomere is related to the probability with which the
extending state occurs and on the probability of a telomerase
complex being at the telomere. Below a critical telomerase
concentration the telomere cannot be sufficiently replenished and
will become eventually critically short, despite the increasing
frequency, with which it is in an extendible state. Lower telomerase
concentration will lead to less frequent extension events and
consequently to slower extension.
For cells with abundance of telomerase the telomeres are
extended beyond that predicted by the theory steady state
length[37]. It is possible that the telomere length control system
has an upper limit on counting telomere length above which it is
incapable of tracking the length of a telomere and therefore the
probability for an open state above this limit is a nonzero
constant[37] explaining the results in human super-telomerase
cells. This effect can be incorporated in the theory, but more studies
are needed to understand how does the extension rate in super-
telomerase cells,relatestotheir telomerase concentration. Currently
available data is inconclusive regarding the relation between the
telomerase concentration and the rate of telomere extension.
One of the conclusions of this paper is that in clinical settings,
telomerase inhibitors need to be administered robustly for a long
time: more than 250 cell divisions, if telomerase is suppressed only
60%. However, low levels of the RNA component of telomerase
lead to a deleterious condition, dyskeratosis congenital, charac-
terized by short telomeres and premature death from bone
marrow failure[46]. A question that can be addressed by the
model presented here is the optimal drug administration schedule
that could limit the effect of telomerase inhibition on the
replicative capacity of the hematopoietic cells and maximize the
suppression of the tumour proliferation.
In clinical settings the grade of a tumour is often quantified
histologically in terms of the mitotic index[47,48], i.e. the fraction
of mitotic spreads visible under a microscope in a given slice of
tissue. Most cells in real tumours do not divide at all times, because
otherwise a single cell after 60 divisions will create approximately
10
20 cells, more than the number of cells in the human body. How
is the telomere derived proliferative potential related to the mitotic
index? The mitotic index of a cell population is between the
smallest and the largest proliferative potential. The lowest
proliferative potential of a dividing cell after n cell divisions is
log2(n+1), when only one of the two daughter cells divides at each
cell division. This will correspond to a stem cell renewing itself and
a non-dividing progenitor cell. The maximum is n, when every
daughter cell divides at each cell division. The mitotic index
depends on many factors that limit and stimulate cell proliferation
and telomere length is one of them. In a tumour in the presence of
telomerase inhibition different proliferating cells will most likely be
exposed to a different level of telomerase inhibition and will
require different time to stop dividing. Several studies have shown
positive correlations between the median survival time of cancer
patients and the average telomere length of the tumour
cells[49,50]. Telomerase expression levels are also negatively
correlated with the median survival time[51]. Therefore, the
telomere related proliferation potential is positively correlated with
the mitotic index and it will be interesting to know how the
dynamics of the mitotic index is related to the telomerase inhibitor
concentration and duration. This will allow the quantification of
the relation between the tumour malignancy and the proliferative
capacity in cancer.
Materials and Methods
A minimal model capturing the biological observations is
described by the equation
ei tz1 ðÞ ~ei t ðÞ {bi t ðÞ zDisge i t ðÞ ðÞ pe i t ðÞ ðÞ hi t ðÞ ½  , i~1...N: ð1Þ
Here N is the number of telomeres, ei(t) is the length of the ith
telomere at time t, bi(t) is the telomere basal loss, g(ei(t)) is the
probability that a telomere is in an extendible state. Di is the
number of base pairs added to the ith telomere during an
elongation event, p is the probability that telomerase is in the
neighbourhood of the ith telomere, and hi is the probability for
telomerase association with the ith telomere. The binary function
s is 1 with probability g(ei(t))p(ei(t))hi(t) and 0 with probability
12g(ei(t))p(ei(t))hi(t), because the three probabilities are indepen-
dent.
Two regimes of telomerase-telomere interaction can be
identified that depend on the telomerase concentration. At a very
high telomerase concentration, as in the supertelomerase cells,
multiple telomerase complexes can be available for the elongation
of each telomere and every time an extendible state occurs
telomerase is available to associate with each telomere. The
telomere length in this regime can be limited by the frequency at
which the extendible state occurs and by the telomerase repeat
addition processivity. The extension of different chromosome ends
is uncorrelated, because the number of telomerase complexes is
larger than the number of telomeres. As the number of telomerase
complexes is reduced below the number of short telomeres, a new
regime of adaptive control occurs in which telomerase levels limit
the telomere length. In this situation the telomere length is
controlled by the probability for a telomerase complex to be at a
particular telomere, by the length dependent probability of this
telomere to be in an open state at that time, and by the telomerase
processivity. In n number of cell divisions the telomere will be
extended to a length e~ mD{nb ðÞ where m is the number of
Telomeres and Telomerase
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added base pairs (bp), and b is the number of bp lost at each cell
division (basal telomere loss). In the model used here for N equal
telomeres and M telomerase molecules, the probability p(ei(t)) is
assumed to be equal to 1 if telomerase is over expressed (as in
super-telomerase cells) i.e. M$N and it is equal to M/N if M,N.
This simple approximation is based on the assumption that
telomerase is reliably ‘‘delivered’’ to the telomeres. The probability
that a telomere is in an open state, g(ei(t)) in S. cerevisiae, is well
approximated by a logistic regression[33], which can be viewed as
describing the statistical properties of a system with binary
occupation of its states, 0 or 1 (nonextendible, extendible). The
logistic function specifies the type of feedback control that the
telomere length exercises on its elongation and in budding yeast
for fixed telomerase concentration
ge i t ðÞ ðÞ ~
1
1ze ei{m ðÞ =T , ð2Þ
where m, and T are constants (Fig. 2). When the telomere length is
equal to m, the probability for an open state is equal to the
probability for a closed state=K, while T controls the statistical
fluctuations. The parameters in the model are fixed by average
experimental values: average telomere length 26000 bp (appro-
priate for human cancer cells); average basal loss 2100 bp;
number of telomerase complexes at equilibrium 250; number of
base pairs added by telomerase 2250. The average extension rate
per cell division can be used to determine the parameters in the
feedback control function. Assuming that there are 50 telomerase
complexes and 92 telomeres in a cell, the steady state is
determined by the condition that on the average the basal loss
balances the added telomere base pairs by telomerase[33].
Mathematically this means that
0~{100z
250p
1ze
eeq{m ðÞ
.
T
, ð3Þ
where the factor p accounts for the ratio of the number of
telomeres to the number of telomerase complexes and eeq=6000
is the telomere equilibrium length. In this approximation it is
assumed that all telomeres are of equal length and ei is replaced by
e. From this equation, it follows that the parameters in the
feedback control function can be fixed to: m=7025 bp (corre-
sponding to a probability for an open state=K) and T=1000 bp
for p=50/92. Here p is equivalent to the telomerase concentra-
tion expressed as a fraction of the number of telomeres.
Telomerase inhibition results in lower values of the steady state
telomere length, eeq.
The theory discussed in the previous section (Eqn. (1)) can be
cast in the form of a differential equation when the time scale of
interest is large compared to the cell division time. In this limit the
model is
de t ðÞ
dt
~{bt ðÞ z
pD
1ze e{m ðÞ =T : ð4Þ
This differential equation cannot be solved explicitly, but several
limits on the parameters of the logistic function can be set from it.
When the telomere length is equal to the steady state length
(eeq=6000), the left hand side of Eqn. (4) is zero. This leads to the
following relation between the telomerase concentration, p and the
parameters m and T:
6000~mzT ln pD=b{1 ðÞ : ð5Þ
At p=50/92, b=100 bp/cell division, and D=250 bp/cell
division the relation between m and T is m=6000+1.025T. On the
other hand Eqn. (5) sets a limit on the parameter T because p is a
concentration with a maximum value of 1 when e-.0. The
relation is p=0.4+e
2m/T. This means that e{m=Tƒ0:6 or
equivalently T#m/5.12=6000+1.025T. From the last relation
follows that the maximum value of T and m, which will guarantee
that the steady state length of the telomere is 6000 bp are
Tmax=1467 bp and mmax=7504 bp respectively. The parameter
T sets the slope of the sigmoid curve displayed in Fig. 2 and m sets
the value at which the probability for an open state is equal to K.
This result means that to maintain telomere length at 6000 the
slope of the curve describing the frequency extendible state cannot
be larger than a certain number. This slope is given by the
derivative of the p with respect to e at e=m and is equal to
{0:25=T. In this study the value T=1000 is assumed, which is
close to the maximum value and the results presented here are a
lower limit to the speed with which telomerase extends a telomere,
i.e. the worst case scenario for treatment and more quantitative
data with different human cells will be useful to better quantify the
values of the parameter in the theory.
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